Cargando…

380. Characterizing Host Factors, Treatment Strategy, and Clinical Outcomes of Group A Streptococcus Orthopedic Infections

BACKGROUND: The annual incidence of invasive β-hemolytic group A streptococcus (GAS) infections in the United States is approximately 3.8 cases per 100,000 patients with 10–30% mortality. But data in GAS orthopedic infections is limited. We sought to characterize patient factors, medical and surgica...

Descripción completa

Detalles Bibliográficos
Autores principales: Nadeem, Naiha, Saraiya, Nidhi, Nori, Priya, Szymczak, Wendy, Boland-Reardon, Carmel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810628/
http://dx.doi.org/10.1093/ofid/ofz360.453
_version_ 1783462298905477120
author Nadeem, Naiha
Saraiya, Nidhi
Nori, Priya
Szymczak, Wendy
Boland-Reardon, Carmel
author_facet Nadeem, Naiha
Saraiya, Nidhi
Nori, Priya
Szymczak, Wendy
Boland-Reardon, Carmel
author_sort Nadeem, Naiha
collection PubMed
description BACKGROUND: The annual incidence of invasive β-hemolytic group A streptococcus (GAS) infections in the United States is approximately 3.8 cases per 100,000 patients with 10–30% mortality. But data in GAS orthopedic infections is limited. We sought to characterize patient factors, medical and surgical management, and clinical outcomes from GAS orthopedic infections at our medical center. METHODS: A total of 12 patients with GAS orthopedic infections (necrotizing fasciitis, osteomyelitis, prosthetic joint infection, septic arthritis, or tenosynovitis) from July 2017 and March 2019 were included. Medical records were reviewed for site of positive GAS culture (blood, wound, joint fluid, or tissue cultures), demographics, comorbidities, surgical management, and antibiotic regimen and duration. The primary outcome was cure at 90 days defined as clinical improvement without recurrent or new infection, or further surgical or medical management at 90 days after treatment completion. The secondary outcome was erythrocyte sedimentation rates (ESR) before and after treatment. RESULTS: The median age of the 12 patients was 56 years (range 3–75); 58% were female and 58% had a body mass index ≥30 kg/m(2). The median Charlson comorbidity index score was 3 (range 0–7) with 58% having diabetes mellitus. Two patients had either rheumatoid arthritis or monoclonal gammopathy (Table 1). Most patients had severe infections; 33% with necrotizing fasciitis and 25% with orthopedic implants. All patients had an elevated initial ESR, including 75% with ESR >40 mm/h. 92% required surgery, including 42% amputations and 17% prosthesis removals. Patients were mostly treated with β-lactams and vancomycin (92%); only 50% received clindamycin or linezolid. Most patients (75%) required at least 2 weeks of antibiotics. Five patients (42%) were not cured at 90 days, and 1 died of infectious complications (Table 2). CONCLUSION: Severe GAS orthopedic infections necessitate both surgical management and prolonged antibiotics. 42% of our patients were not cured at 90 days and most eventually required amputation. Toxin mediators, clindamycin and linezolid, were underutilized. Chronic suppressive antibiotics should be considered for patients with orthopedic implants, especially those with durable immune suppression. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6810628
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68106282019-10-28 380. Characterizing Host Factors, Treatment Strategy, and Clinical Outcomes of Group A Streptococcus Orthopedic Infections Nadeem, Naiha Saraiya, Nidhi Nori, Priya Szymczak, Wendy Boland-Reardon, Carmel Open Forum Infect Dis Abstracts BACKGROUND: The annual incidence of invasive β-hemolytic group A streptococcus (GAS) infections in the United States is approximately 3.8 cases per 100,000 patients with 10–30% mortality. But data in GAS orthopedic infections is limited. We sought to characterize patient factors, medical and surgical management, and clinical outcomes from GAS orthopedic infections at our medical center. METHODS: A total of 12 patients with GAS orthopedic infections (necrotizing fasciitis, osteomyelitis, prosthetic joint infection, septic arthritis, or tenosynovitis) from July 2017 and March 2019 were included. Medical records were reviewed for site of positive GAS culture (blood, wound, joint fluid, or tissue cultures), demographics, comorbidities, surgical management, and antibiotic regimen and duration. The primary outcome was cure at 90 days defined as clinical improvement without recurrent or new infection, or further surgical or medical management at 90 days after treatment completion. The secondary outcome was erythrocyte sedimentation rates (ESR) before and after treatment. RESULTS: The median age of the 12 patients was 56 years (range 3–75); 58% were female and 58% had a body mass index ≥30 kg/m(2). The median Charlson comorbidity index score was 3 (range 0–7) with 58% having diabetes mellitus. Two patients had either rheumatoid arthritis or monoclonal gammopathy (Table 1). Most patients had severe infections; 33% with necrotizing fasciitis and 25% with orthopedic implants. All patients had an elevated initial ESR, including 75% with ESR >40 mm/h. 92% required surgery, including 42% amputations and 17% prosthesis removals. Patients were mostly treated with β-lactams and vancomycin (92%); only 50% received clindamycin or linezolid. Most patients (75%) required at least 2 weeks of antibiotics. Five patients (42%) were not cured at 90 days, and 1 died of infectious complications (Table 2). CONCLUSION: Severe GAS orthopedic infections necessitate both surgical management and prolonged antibiotics. 42% of our patients were not cured at 90 days and most eventually required amputation. Toxin mediators, clindamycin and linezolid, were underutilized. Chronic suppressive antibiotics should be considered for patients with orthopedic implants, especially those with durable immune suppression. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6810628/ http://dx.doi.org/10.1093/ofid/ofz360.453 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Nadeem, Naiha
Saraiya, Nidhi
Nori, Priya
Szymczak, Wendy
Boland-Reardon, Carmel
380. Characterizing Host Factors, Treatment Strategy, and Clinical Outcomes of Group A Streptococcus Orthopedic Infections
title 380. Characterizing Host Factors, Treatment Strategy, and Clinical Outcomes of Group A Streptococcus Orthopedic Infections
title_full 380. Characterizing Host Factors, Treatment Strategy, and Clinical Outcomes of Group A Streptococcus Orthopedic Infections
title_fullStr 380. Characterizing Host Factors, Treatment Strategy, and Clinical Outcomes of Group A Streptococcus Orthopedic Infections
title_full_unstemmed 380. Characterizing Host Factors, Treatment Strategy, and Clinical Outcomes of Group A Streptococcus Orthopedic Infections
title_short 380. Characterizing Host Factors, Treatment Strategy, and Clinical Outcomes of Group A Streptococcus Orthopedic Infections
title_sort 380. characterizing host factors, treatment strategy, and clinical outcomes of group a streptococcus orthopedic infections
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810628/
http://dx.doi.org/10.1093/ofid/ofz360.453
work_keys_str_mv AT nadeemnaiha 380characterizinghostfactorstreatmentstrategyandclinicaloutcomesofgroupastreptococcusorthopedicinfections
AT saraiyanidhi 380characterizinghostfactorstreatmentstrategyandclinicaloutcomesofgroupastreptococcusorthopedicinfections
AT noripriya 380characterizinghostfactorstreatmentstrategyandclinicaloutcomesofgroupastreptococcusorthopedicinfections
AT szymczakwendy 380characterizinghostfactorstreatmentstrategyandclinicaloutcomesofgroupastreptococcusorthopedicinfections
AT bolandreardoncarmel 380characterizinghostfactorstreatmentstrategyandclinicaloutcomesofgroupastreptococcusorthopedicinfections